EMAIL THIS PAGE TO A FRIEND

In vitro cellular & developmental biology. Animal

Evaluating cytotoxic effect of nanoliposomes encapsulated with umbelliprenin on 4T1 cell line.


PMID 27620062

Abstract

Cytotoxicity of umbelliprenin has been found in various cancer cell lines such as, prostate, breast, CLL, and skin. Encapsulating chemotherapeutic agents with nanoliposomes have been resulted in improved cytotoxicity effects than their free forms. However, whether nanoliposomal form of umbelliprenin could have higher cytotoxic effect than free umbelliprenin is not clarified yet. After synthesizing umbelliprenin, different concentrations (3, 6, 12, 25, 50, 100, 200xa0μg/ml) applied on the mouse mammary carcinoma cell line (4T1) for 24, 48, and 72xa0h at 37°C. Afterwards, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was performed to analyze cytotoxicity. MTT assay results showed that IC50 of umbelliprenin in dimethyl sulfoxide (DMSO) (30.92, 30.64, and 62.23 for 24, 48, 72xa0h incubation, respectively) decreased (5.8, 5.0, 3.5 for 24, 48, 72xa0h incubation, respectively) when encapsulated with nanoliposomes. Nanoliposomal umbelliprenin cytotoxicity affected cell viability in concentration and time-dependent manner. Our study recommended nanoliposomal umbelliprenin as the most effective chemotherapeutic agent against the mouse mammary carcinoma cell line viability. Future in vivo studies and clinical trials are needed.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P1223
L-α-Phosphatidylethanolamine, dioleoyl, ≥99% (GC), ≥98% (TLC), lyophilized powder
C41H78NO8P